Interventional technology developer AngioDynamics has signed an agreement to acquire RadiaDyne, a private medical diagnostic and device company that develops patient radiation dose monitoring technology.
The deal will broaden AngioDynamics' oncology business, adding RadiaDyne's OARtrac radiation dose monitoring platform to its portfolio, the company said. RadiaDyne also makes IsoLoc/ImmobiLoc, endorectal tools that reduce prostate motion and radiation toxicity, and Alatus, a vaginal balloon packing system that improves dosimetry, according to AngioDynamics.
RadiaDyne's 12-month revenues exceeded $6 million. The acquisition is expected to close by the end of September, AngioDynamics said.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)